Drug major Sun Phrama's shares gained over 5 per cent during Tuesday's morning trade session after clarifications by the company on various issues including its dealing with Suraksha Realty.
At 10.48 a.m, its stocks traded at Rs 419.05, up Rs 20.70 or 5.20 per cent from its previous close of Rs 398.35 on Monday.
The company in a regulatory filing said that the its distribution related to India Domestic Formulations Business shall be transitioned from Aditya Medisales Ltd., the current distributor, to a wholly owned subsidiary of Sun Pharma.
"This change will be made effective by Q1FY20, post receipt of all requisite regulatory approvals," the statement said.
This transaction was expected to be concluded in FY19, said the company.
The company also clarified that "neither any loans nor guarantees have been given to Suraksha Realty".
"The company states unequivocally that it does not have any financial transactions with Suraksha Realty."
--IANS
ravi/in
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
